Token Count
1 GEN = 0.01 $

Genexi accelerates the transition of cutting-edge biotech projects from research to the market

Token holders

Support the international community to fight counterfeit drugs with digital tools


We pledge to provide regulatory, advisory and research expertise to improve the quality of your life


The development of biotechnology holds tremendous promises for the developing world

Genexi Ecosystem

Transactions via Smart Contracts

  • Efficiency. Eliminate a vast chain of middlemen
  • Speed. No need to process documents manually
  • Security. The highest level of data encryption
  • Trust. Absolute confidence in their execution
  • Transparency. Fully visible T&Cs to all relevant parties

Blockchain Solution for Supply Chain Quality Management

  • Effective fraud detection process
  • Fast access to the supply chain data
  • Full traceability and reduced inherent risks
  • A link between physical and information flows
  • Information sharing between the different stakeholders

Biotech Vendor

  • Focus on the target audience
  • Mitigation of supplier risks
  • Protection of your brand
  • Reduced marketing expenses
  • Increased on-boarding speed
  • Optimised performance

Token GEN

  • Right for specific access to the platform
  • Medium of exchange within the whole ecosystem
  • Reward for your loyalty via bonus programs
  • Transfer of value between distribution chain partners

Our Insight

Biotechnology involves transformative technologies for medicine, environment and agriculture. The use of living systems and organisms to make or develop products has increased dramatically over the recent years.

An increasing demand for biotechnology-based diagnostics and therapeutics solutions such as DNA sequencing, tissue engineering and regeneration, cell-based assay promotes funding to support R&D and new product development endeavours.

Growth Opportunities

2017 was a record year for biotech investments. VC funding for digital health accounted for nearly $4.5 billion which is approximately 109% up in comparison with 2016.

According to our estimates, the world biotechnology market value will cross $2 trillion in 2018 with 67% of manufacturers revenue coming from the sales of biotech and pharmaceutical products.

Key Biotechnology Areas

DNA Sequencing

Genome analysis cost has significantly reduced because of the emergence of second and third generation sequencing technologies (NGS). As a whole genome scanning cost falls the personalised medicine grows, a new understanding of the genetic variation of individuals is appeared. Moreover, unidentified vast regions of DNA now are clear and unlocked.

Stem Cell Therapy

Medical scientists and drug developers have tremendous opportunities to test drugs in the lab as they see how stem cells are able to grow into any of the body’s specialised cells. However, their major goal and perspective is to rise to an era of regenerative medicine where life-altering injuries and deadly diseases are not just treated, but cured.

Gene Therapy

MicroRNA is a new way of diagnosing and treating disease. MicroRNAs prevents the translation of messenger RNA into proteins by breaking down of messenger RNA. The absence or presence of specific microRNAs in various cells is held by specific human diseases, including cancer, viral infection, metabolic disorders and inflammatory disease.

Tissue Engineering

Biotechnology gives good grounds for expecting cheaper and safer vaccines. Alternatively DNA vaccines use a piece of genetic code for a pathogen instead of using a weakened or killed virus use a piece of genetic code for a pathogen. Traditional methods involve using eggs to grow vaccines. DNA vaccines can be made cardinally quicker and production is more bigger and innovative.

Synthetic Biology

Synthetic biology includes a construction of DNA as a basis for building organisms that can perform specific tasks. It is a major part in developing new biofuels that can break the world’s addiction to petroleum. This sphere draws a great attention for its potential in providing cleaner and renewable sources of fuel. Thus it is changing everything from the way drugs are made to the way industrial goods are manufactured.

Systems Biology

Systems biology focuses on understanding the interaction between a series of genes and their interactions with proteins. Advances in computing, the falling cost of genetic analysis, and other technological advances made this data-intensive approach possible.

Cancer Immuno Therapy

Accelerated breakthroughs in Adoptive T-cell therapies will contribute to the growth of immuno-oncology market during the next 10 years.

Grant Portfolio

Bacteriorhodopsin is a photosensitive protein of purple membranes of Halobacterium salinarum microorganisms living in salt lakes, where the salt concentration is 6 times higher than in the seawater.

Application areas:

Pharmaceutics and cosmetology

Treatment of psoriasis, asthma, conjunctiviti


Plant growth stimulation


Development of biocomputers


The RESTET skin regeneration system is the flagship project focused on the research and development of next generation medicines based on bacteriorhodopsin - one of the most promising means of fighting against diseases such as psoriasis, atopic dermatitis, neurodermatitis and acne. RESTET is a unique breakthrough in the field of molecular biocosmetology and has no side effects. The methods of treatment are effective for any age, sex, duration of skin lesions. The unique process of the synthesis of bacteriorhodopsin has been patented in different countries, including Germany, France, China, Iran and South Korea.


  • Transparency in the use of funds
  • Instant custody without intermediaries
  • Decentralised process of funding technology
  • International reach and flexibility
  • Early contributors will have more liquidity in early stage companies

Genexi Foundation

  • Use blockchain technologies to publish funding and grant information in real time
  • Promote and support Genexi Ecosystem
  • Bring decentralised protocols and digital tools into the biotech field
  • Empower researchers and entrepreneurs to implement their innovative ideas
  • Build a global community of biotech enthusiasts


Katrina Arden


A founder of Blockchain Law Group, she is a licensed attorney in the USA and in the Russian Federation. She has extensive experience handling various domestic and international issues, including tax compliance and security regulations, structuring international transactions and working on the multimillion dollar lawsuits involving securities fraud. For certain large token purchases, Genexi is able to use escrow services provided by Blockchain Law Group. Use of escrow is optional and does not apply to regular purchases. Escrow may be available upon request only. A separate escrow agreement is required.

Aleksei Zheliaskov

Founder, CEO

President of JFSC Atlant and a founder of Genexi with over 12 years of professional experience in investment management. Alexey is a serial entrepreneur who has built multiple successful companies in financial and real estate sector. His current focus lies within venture capital business, where he encourages innovation and facilitates entrepreneurship providing both his management and marketing expertise to young entrepreneurs. He seeks to make investments that solve critical social and environmental issues.

Aleksei Kirillov

Co-Founder, COO

Alexey started his career in the private sector – working in sales, marketing and consulting Russian multi-national companies. Prior to founding Genexi, he worked extensively with Swiss wealth management firms to support the expansion of their operations to CIS markets. In 2012 he started investing in the crypto space and since then became a cryptocurrency trader and portfolio manager, overseeing a $20 million portfolio.

Roman Gilvanov

Managing Director

Prior to joining Genexi, Roman acted as CEO of IronFX Russia – one of the largest European FX brokerages with more than 80 branch offices around the world. Throughout his career, Roman held project manager positions in various IT start-ups, managing 15 local teams on three continents.

Andrew Zharkov

Head of Finance

Andrew is an experienced finance director who has undertaken a number of senior finance roles within the financial services industry where he has invariably improved the role of finance in supporting their business activity. At Genexi, he is responsible for the finance activities of the foundation covering reporting, planning, control of day to day transactions and financial support to the sector teams. Andrew began his career at Price Waterhouse and has subsequently worked with Aegon, Volkswagen and Legal & General.


  • 2014

    • Primary Scientific and Medical Research.
  • Q1 2017

    • GENEXI Establishment.
  • Q3 2017

    • Ecosystem and Platform Development.
  • Q1 2018

    • Low Level Design Launch.
  • Q3 2018   

    • Ecosystem Alpha Version Testing.
  • Q4 2018

    • Smart-Contract Development and Testing. Grant Application Program Launch.
  • H1 2019

    • Ecosystem Complete Version Launch.
  • H2 2019

    • Official Public GENEXI Accelerator Report.
  • 2020

    • Further Ecosystem Development and Scaling.

White Paper

Investment Info
Token Info
Token GEN
Platform Ethereum
Type ERC20
Token Price 1 GEN = 0.01 $
Token Count 12,000,000,000
Pre-Sale Start Date 2018-May-01
Pre-Sale End Date 2018-May-31
Crowd Sale Start Date 2018-June-01
Crowd Sale End Date 2018-August-31

Write a review

Note: HTML is not translated!
    Bad           Good
This ICO is being reviewed in detail. This section will be updated soon.

GENEXI - Accelerating Biotech Breakthroughs

Top Raised ICOs - Ending soon

ICOs being viewed at the moment

DST - DST Aims To Build A Silver Ecosystem With Blockchain Technology(DST)
Ending: 15 August
Zichain - your gateway to the world of crypto finance
Ending: 15 August
ENTRY - ENTRY The People’s Bank of Blockchain
Ending: 31 August
Sidera - Sidera Blockchain Technologies (eQUOS)
Ending: 30 September
GGRocket - blockchain powered trustless virtual economy and AI driven big data analytics for the gaming industry (GGR)
Ending: 30 September
Litenett - The Multimedia Social Network
Ending: 05 November
EO Coin - EO.Trade Crypto Exchange. One Coin. Four platforms.
Ending: 31 August
PeruCoin - The ICO that will change Peru (PRU)
Ending: 06 September
Metabase - A High Performance Blockchain and Smart Op-Codes Platform for Next Generation Businesses.
Ending: 18 September
Pigzbe - A piggy-wallet™ not a piggy bank (WLO)
Ending: 19 September
LeoPays - Social Business Network (LPC)
Ending: 11 November
i-chain - Insurance Platform and Ecosystem
Ending: 16 May
Jinbi - The Golden ICO (JNB)
Ending: 30 September
Usechain - The First Mirror Identity Blockchain (UST)
Ending: 08 August
Ending: 30 September